Effect of Alendronate in Patents with Osteoporosis and Chronic Kidney Disease

Effect of Alendronate on Bone Densitometry in Osteoporetic Chronic Kidney Disease Stage 3a-3b

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180506039549N1

Enrollment

Registered

2018-10-22

Start date

2018-08-06

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease Stage 3a-3b. Chronic kidney disease, stage 3 (moderate)

Interventions

Intervention 1: Intervention group: Alendronate 70mg Tablet Produced by Abidi Company Will Orally be Administered to This Group once a Week Before Meals, with a Glass of Water for 6 Months. Interventi

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Osteoporotic Patients with Chronic Kidney Disease Patients over 18 years of Age

Exclusion criteria

Exclusion criteria: Patients with hyperparathyroidism Patients with hypoparathyroidism Patients with normal Densitometry

Design outcomes

Primary

Measure	Time frame
Bone density in patients with Chronic Kidney Disease Stage 3a-3b. Timepoint: Before and 6 months after study. Method of measurement: Densitometry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShokouh Shayanpour

Ahvaz University of Medical Sciences

shayanpor.sh@ajums.ac.ir+98 61 3333 7077

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026